Manuscripts and Publications

2021
Fawzy A, Woo H, Balasubramanian A, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2021.  Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study.. Chronic Obstr Pulm Dis. 8(3):326-335.
Woo H, Brigham EP, Allbright K, Ejike C, Galiatsatos P, Jones MR, Oates GR, Krishnan JA, Cooper CB, Kanner RE et al..  2021.  Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 204(5):536-545.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
2020
Galiatsatos P, Woo H, Paulin LM, Kind A, Putcha N, Gassett AJ, Cooper CB, Dransfield MT, Parekh TM, Oates GR et al..  2020.  The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease.. Int J Chron Obstruct Pulmon Dis. 15:981-993.
Smith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, Bertoni A, Coxson HO, Cooper C, Couper DJ et al..  2020.  Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults.. JAMA. 323(22):2268-2280.
Paulin LM, Gassett AJ, Alexis NE, Kirwa K, Kanner RE, Peters S, Krishnan JA, Paine R, Dransfield M, Woodruff PG et al..  2020.  Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers.. JAMA Intern Med. 180(1):106-115.
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.. JCI Insight. 5(3)
Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, R Barr G, Krishnan JA, Cooper C, Labaki WW et al..  2020.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.. Chest. 157(4):856-865.
Moll M, Sakornsakolpat P, Shrine N, Hobbs BD, DeMeo DL, John C, Guyatt AL, McGeachie MJ, Gharib SA, Obeidat M'en et al..  2020.  Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.. Lancet Respir Med. 8(7):696-708.
Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, O'Neal WK, Comellas AP, Han MK, Dransfield MT et al..  2020.  Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene.. Chest. 158(6):2333-2345.
Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP et al..  2020.  Comparison of Proteomic Assessment Methods in Multiple Cohort Studies.. Proteomics. 20(12):e1900278.
Kim V, Jeong S, Zhao H, Kesimer M, Boucher RC, J Wells M, Christenson SA, Han MK, Dransfield M, Paine R et al..  2020.  Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects.. Sci Rep. 10(1):20133.
Stott-Miller M, Müllerová H, Miller B, Tabberer M, Baou CEl, Keeley T, Martinez FJ, Han ML, Dransfield M, Hansel NN et al..  2020.  Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:2467-2476.
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Allen RJ, Guillen-Guio B, Oldham JM, Ma S-F, Dressen A, Paynton ML, Kraven LM, Obeidat M'en, Li X, Ng M et al..  2020.  Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 201(5):564-574.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, Cruickshank-Quinn C, Reisdorph N, Petrache I, Labaki WW et al..  2020.  Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.. Netw Syst Med. 3(1):159-181.
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.
2019
Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, R Barr G, Bleecker ER et al..  2019.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.. J Clin Invest. 129(1):169-181.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Halper-Stromberg E, Gillenwater L, Cruickshank-Quinn C, O'Neal WKay, Reisdorph N, Petrache I, Zhuang Y, Labaki WW, Curtis JL, Wells J et al..  2019.  Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma.. Metabolites. 9(8)

Pages